JAMA Oncology Author Interviews
By JAMA Network
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by JAMA Network
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 65
Reviews: 0
Episodes: 113
Description
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
| Episode | Date |
|---|---|
|
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
|
Apr 18, 2024 |
|
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
|
Mar 21, 2024 |
|
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
|
Feb 29, 2024 |
|
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
|
Jan 04, 2024 |
|
Atezolizumab in Combination With Carboplatin in Metastatic TNBC
|
Dec 14, 2023 |
|
Shorter-Course Radiotherapy for Prostate Cancer
|
Oct 05, 2023 |
|
Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer
|
Sep 21, 2023 |
|
A Geospatial Analysis of Disparities in Access to Oncofertility Services
|
Aug 10, 2023 |
|
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
|
Jul 20, 2023 |
|
US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020
|
Jun 29, 2023 |
|
Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer
|
May 25, 2023 |
|
Radiosurgery of Spine Metastasis—NRG/RTOG 0631 RCT Final Results
|
Apr 20, 2023 |
|
Pathologic Complete Response and Clinical Outcomes in Soft Tissue Sarcoma
|
Mar 30, 2023 |
|
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
|
Feb 16, 2023 |
|
Adoption of Innovative Therapies Across Oncology Practices
|
Jan 05, 2023 |
|
Adjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
|
Dec 08, 2022 |
|
Association of DCVax-L With Extension of Survival Among Patients With Glioblastoma
|
Nov 17, 2022 |
|
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
|
Oct 27, 2022 |
|
Prostate-Specific Antigen Screening Rates and Metastatic Prostate Cancer Incidence in the VHA
|
Oct 24, 2022 |
|
Therapy and Survival Patterns in Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy
|
Aug 18, 2022 |
|
Global Association of COVID-19 Pandemic Measures With Cancer Screening
|
Jul 07, 2022 |
|
A Conversation With Dr Kirsten Bibbins-Domingo, JAMA’s New Editor in Chief
|
Jul 05, 2022 |
|
High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade
|
Jun 16, 2022 |
|
Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
|
May 19, 2022 |
|
Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
|
Apr 28, 2022 |
|
Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer
|
Mar 17, 2022 |
|
Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer
|
Feb 17, 2022 |
|
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy
|
Jan 20, 2022 |
|
Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
|
Dec 23, 2021 |
|
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer
|
Nov 18, 2021 |
|
Clinical Outcomes and Toxic Effects of Single-Agent ICI Treatment Among Geriatric Patients With Cancer
|
Nov 04, 2021 |
|
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer
|
Sep 16, 2021 |
|
Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With NSCLC
|
Aug 12, 2021 |
|
Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
|
Jul 01, 2021 |
|
Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
|
Jun 24, 2021 |
|
Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases
|
May 13, 2021 |
|
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC
|
Apr 15, 2021 |
|
Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
|
Mar 25, 2021 |
|
Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase
|
Feb 18, 2021 |
|
Virtual Care Across a Tertiary Cancer Center During COVID-19
|
Jan 07, 2021 |
|
Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases
|
Dec 17, 2020 |
|
Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
|
Nov 12, 2020 |
|
Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia
|
Oct 08, 2020 |
|
Survival and Adjuvant Chemotherapy in Early-Stage NSCLC With vs Without Clinicopathologic Features
|
Sep 17, 2020 |
|
Tailoring Intensity of Surveillance for Prostate Cancer Based on Prediction of Risk Stability
|
Aug 27, 2020 |
|
Presence of ctDNA and CTCs After Chemotherapy and Recurrence of Triple-Negative Breast Cancer
|
Jul 09, 2020 |
|
Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults
|
Jun 18, 2020 |
|
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
|
Jun 04, 2020 |
|
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
|
Apr 16, 2020 |
|
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
|
Apr 09, 2020 |
|
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
|
Feb 13, 2020 |
|
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
|
Jan 16, 2020 |
|
Association Between BMI and Overall Survival in Advanced Non–Small Cell Lung Cancer
|
Dec 26, 2019 |
|
The Role of Maintenance Strategies in Metastatic Colorectal Cancer
|
Dec 19, 2019 |
|
Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer
|
Oct 03, 2019 |
|
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|
Sep 12, 2019 |
|
Women’s Representation Among Lead Investigators of Clinical Trials in Oncology
|
Aug 08, 2019 |
|
Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
|
Jul 25, 2019 |
|
Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers
|
Jun 27, 2019 |
|
Prognostic Potential of Circulating Tumor DNA Measurement in Nonmetastatic Colorectal Cancer
|
May 09, 2019 |
|
Single-Fraction Stereotactic vs Multifraction Radiotherapy for Pain Relief in Patients With Nonspine Bone Metastases
|
Apr 18, 2019 |
|
The Role of Disease Label in Patient Perceptions and Treatment Decisions in the Setting of Low-Risk Malignant Neoplasms
|
Mar 21, 2019 |
|
Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer
|
Feb 21, 2019 |
|
Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation
|
Jan 10, 2019 |
|
Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal BMI
|
Dec 06, 2018 |
|
Surgery vs Radiotherapy in the Management of Gleason Score 9-10 Prostate Cancer and the Risk of Mortality
|
Nov 15, 2018 |
|
Analgesic Use and Risk of Ovarian Cancer in the Nurses’ Health Studies
|
Oct 04, 2018 |
|
Hyperprogressive Disease in Patients With Advanced NSCLC Treated With PD-1/PD-L1 Inhibitors
|
Sep 06, 2018 |
|
Maintenance Treatment and Survival in Patients With Myeloma
|
Aug 09, 2018 |
|
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening
|
Jul 05, 2018 |
|
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade
|
Jun 14, 2018 |
|
Outcomes of Multiple-Gene Sequencing After Diagnosis of Breast Cancer
|
May 10, 2018 |
|
Association of Colon Cancer Survival With ACS Guideline Adherence
|
Apr 12, 2018 |
|
Standard vs Dose-Escalated Radiotherapy in Medium-Risk Prostate Cancer
|
Mar 15, 2018 |
|
Atezolizumab Monotherapy for Patients With Metastatic Urothelial Cancer
|
Feb 08, 2018 |
|
Dietary Inflammatory Potential and Risk of Colorectal Cancer in Men and Women
|
Jan 18, 2018 |
|
Preoperative vs Postoperative CEA and Colon Cancer Outcome
|
Dec 21, 2017 |
|
Critical Lessons From High-Value Oncology Practices
|
Nov 16, 2017 |
|
Prophylactic Surgery for Stage IV Small Intestinal Neuroendocrine Tumors
|
Oct 19, 2017 |
|
Trends in Adult Cancer–Related Emergency Department Utilization
|
Aug 31, 2017 |
|
Prevalence of Cancer in Li-Fraumeni Syndrome Cohort
|
Aug 03, 2017 |
|
Breast Cancer Due to Non–BRCA1 and Non–BRCA2 Mutations in Ashkenazi Jewish Women
|
Jul 20, 2017 |
|
Trends in Reoperation After Initial Lumpectomy for Breast Cancer
|
Jun 05, 2017 |
|
Combined TMPRSS2:ERG and PCA3 RNA Testing for Detection of Prostate Cancer
|
May 18, 2017 |
|
Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors
|
Apr 27, 2017 |
|
Birth Outcomes Among Adolescent and Young Adult Cancer Survivors
|
Mar 23, 2017 |
|
Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Trials
|
Feb 16, 2017 |
|
Delayed Adjuvant Chemotherapy After Lung Cancer Surgery
|
Jan 05, 2017 |
|
Global Burden of Cancer 2015
|
Dec 03, 2016 |
|
Comparison of Vaginal Testosterone Cream or Vaginal Ring
|
Nov 10, 2016 |
|
Association Between Androgen Deprivation Therapy and Risk of Dementia
|
Oct 13, 2016 |
|
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
|
Oct 06, 2016 |
|
Prognostic Factors for Local Control in Breast Cancer With Boost vs No Boost
|
Sep 08, 2016 |
|
ESR1 Mutations in Metastatic Breast Cancer
|
Aug 11, 2016 |
|
Outcomes for Biomarker-Based Treatment Strategies in Refractory Malignant Neoplasms
|
Jun 06, 2016 |
|
Physiologic Frailty in Hematopoietic Cell Transplantation Patients
|
Jun 02, 2016 |
|
Lifestyle Associations With US Cancer Incidence and Mortality
|
May 19, 2016 |
|
Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer
|
Apr 14, 2016 |
|
Prostate-Specific Antigen Screening and Selective Treatment
|
Mar 24, 2016 |
|
Effect of Long-term Use of Aspirin on the Risk for Cancer
|
Mar 03, 2016 |
|
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer
|
Feb 11, 2016 |
|
Molecular Profiling in Pediatric Tumors
|
Jan 28, 2016 |
|
Delayed Initiation of Chemotherapy and Breast Cancer
|
Dec 10, 2015 |
|
Erlotinib and the Risk of Oral Cancer
|
Nov 05, 2015 |
|
Breast Tumor Characteristics and Biennial vs Annual Mammography
|
Oct 20, 2015 |
|
Agent Orange Exposure and Monoclonal Gammopathy
|
Sep 03, 2015 |
|
Differences in the Acute Toxic Effects of Breast Radiotherapy
|
Aug 06, 2015 |
|
Trends in Advance Care Planning in Patients With Cancer
|
Jul 09, 2015 |
|
Obesity and Postmenopausal Invasive Breast Cancer Risk
|
Jun 11, 2015 |
|
The Global Burden of Cancer 2013
|
May 28, 2015 |
|
Chemoresistance After Consumption of Fish and Fish Oil
|
Apr 02, 2015 |
|
21-Gene Recurrence Score Assay for Breast Cancer
|
Mar 05, 2015 |
|
Hereditary Diffuse Gastric Cancer Syndrome
|
Feb 12, 2015 |